Novo Nordisk about to receive important CHMP decision on Wegovy label extension

Novo Nordisk’s obesity drug Wegovy is expected to be assessed this week for a potential label extension in the EU. 
Photo: Staff/Reuters/Ritzau Scanpix
Photo: Staff/Reuters/Ritzau Scanpix

It is by no means insignificant when CHMP is expected to decide this week whether Novo Nordisk’s obesity drug Wegovy should be recognized for its ability to prevent serious cardiovascular diseases. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading